Literature DB >> 1262919

Cerebral arterial spasm. Part 5: in vitro contractile activity of vasoactive agents including human CSF on human basilar and anterior cerebral arteries.

G S Allen, C J Gross, L A French, S N Chou.   

Abstract

In vitro experiments were performed with a small volume chamber to determine the contractile activity of various vasoactive agents on human basilar and anterior cerebral arteries. Cumulative log-dose response curves were obtained for most of the agents tested including serotonin and three different prostaglandins; many of these curves were found to be similar to curves previously obtained with canine cerebral arteries. It was concluded from these similarities that canine cerebral arteries are a good in vitro model for studying human cerebral arterial spasm. It was also demonstrated that human cerebrospinal fluid, collected up to 17 days after a subarachnoid hemorrhage from patients with clinical and angiographic evidence of cerebral arterial spasm, would cause large, dose-dependent contractions in human anterior cerebral arteries.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1262919     DOI: 10.3171/jns.1976.44.5.0594

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Aetiology of cerebral arterial spasm following subarachnoid haemorrhage: evidence against a major involvement of 5-hydroxy-tryptamine in the production of acute spasm.

Authors:  D J Boullin; G H Du Boulay; A T Rogers
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

2.  Effect of intracisternal thromboxane A2 analogue on cerebral artery permeability.

Authors:  M Zuccarello; T Sasaki; N F Kassell; M Yamashita
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Effects of intracranial dopamine perfusion: behavioural arousal and reversal of cerebral arterial spasm following surgery for clipping of ruptured cerebral aneurysms.

Authors:  D J Boullin; C B Adams; J Mohan; A R Green; T M Hunt; G H du Boulay; A T Rogers
Journal:  Proc R Soc Med       Date:  1977

4.  Effects of nifedipine on artificially induced femoral and basilar artery contraction in vitro and reversal of acute and chronic vertebral basilar spasm by orally administered nifedipine in dogs.

Authors:  G S Allen; A L Bahr; S B Banghart
Journal:  Neuroradiology       Date:  1978       Impact factor: 2.804

5.  Relationship between presence of vasoconstrictor activity in cerebrospinal fluid and time after subarachnoid haemorrhage from rupture of cerebral arterial aneurysms.

Authors:  T M Hunt; G H Du Boulay; W P Blaso; D M Forster; D J Boullin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-07       Impact factor: 10.154

6.  Contractile effects of perivascularly applied vasopressin on the pial artery of the cat brain.

Authors:  M Nakai
Journal:  J Physiol       Date:  1987-06       Impact factor: 5.182

Review 7.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

8.  Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man.

Authors:  D J Boullin; S Bunting; W P Blaso; T M Hunt; S Moncada
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

9.  Models for investigating the aetiology of cerebral arterial spasm: comparative responses of the human basilar artery with rat colon, anococcygeus, stomach fundus, and aorta and guinea-pig ileum and colon.

Authors:  D J Boullin; T M Hunt; A T Rogers
Journal:  Br J Pharmacol       Date:  1978-06       Impact factor: 8.739

10.  Effect of lesioning of medullary catecholamine neurons or the median eminence on the development of cerebral vasospasm in the squirrel monkey.

Authors:  N A Svendgaard; Y Shiokawa; T J Delgado-Zygmunt; M A Arbab; G Skagerberg; A Brun
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.